ibandronate [Bonviva/Boniva] + ibandronate [Bonviva/Boniva] + Alendronate

ApprovedCompleted
0 watching 0 views this week๐Ÿ”ฅ Hot
85
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
โœ“
Phase 3
5
Approved
Indication / Disease

Post-Menopausal Osteoporosis

Conditions

Post-Menopausal Osteoporosis

Trial Timeline

Jul 1, 2007 โ†’ Apr 1, 2010

About ibandronate [Bonviva/Boniva] + ibandronate [Bonviva/Boniva] + Alendronate

ibandronate [Bonviva/Boniva] + ibandronate [Bonviva/Boniva] + Alendronate is a approved stage product being developed by Roche for Post-Menopausal Osteoporosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00503113. Target conditions include Post-Menopausal Osteoporosis.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT00503113ApprovedCompleted